May. 19 at 11:02 PM
The XBI is off 7% since last Wednesday trading lower 4 days in a row.
We count 28 commercial-stage oncology focused bios with MCs over
$300MM. 5 of the 28 are up the last 4 days while the other 23 are lower.
$JAZZ is 1 of the 5 higher mostly due to today's gains after UBS increased their target price from
$188 to
$307 per share on Ziihera potential.
$FENC is up almost 50% after reporting a rare beat for Q126. While anything is possible, we'd remind investors FENC has been for sale for years. FENC executives were promised huge bonuses if they could get
$400MM for FENC the year after PedMark's approval. The bonuses were extended at least 1 year (though we stopped tracking FENC after that).
$GERN is the biggest loser in the group but GERN's EV is now not 2.5X management FY26 guidance. The long anticipated read in myelofibrosis continues to near.
$NUVB We have no idea what NUVB is down. Anyone? Ibrozi's PDUFA date for the sBLA is 1/4/27
$RIGL is still up ~10% from before the Arvinas transaction
